Born in 1966, Dr. Hồ Nhân spent much of his early life in New York, where he developed his passion for biopharmaceutical research. He earned Ph.D. in Biotechnology from the University of Arizona.
With nearly a decade of experience working in the United States, Dr. Hồ Nhân gained deep expertise in both scientific research and corporate management within the biotechnology sector.
Beyond biotech, he also built a solid background in finance and investment. During his time in the U.S., he led numerous mergers and acquisitions (M&A) involving pharmaceutical companies, medical device firms, and hospitals. He also served as a healthcare equity valuation advisor for an investment fund based in Hong Kong.
In 1996, Dr. Nhân returned to Vietnam with a bold mission: to build a world-class, innovation-driven pharmaceutical biotechnology enterprise in his home country. One year later, he founded Việt Cơ Company Limited, whose name later changed into Nanogen Pharmaceutical Biotechnology JSC.
As Chairman and CEO, he positioned Nanogen as a pioneer in gene-to-therapy biopharmaceutical development, focused on delivering affordable and innovative treatments across Vietnam and Southeast Asia.
Guided by the principle of “advanced medicine at an affordable cost”, Nanogen contributed to the leap of Vietnam’s pharmaceutical landscape with a wide range of biological products, including:
The company also developed key chemical pharmaceuticals such as:
Dr. Nhân held numerous prestigious US patents for his innovations: proprietary cell culture medium, PEG-interferon lambda 1 conjugates (PEG-IFNλ1) and methods of treating viral infections.
He has a hands-on leadership style and steadfast commitment to scientific integrity, personally overseeing the majority of Nanogen’s research and development activities.
When the global COVID-19 pandemic struck, Dr. Hồ Nhân responded decisively. Under his leadership, Nanogen developed Nanocovax, Vietnam’s first domestically produced COVID-19 vaccine based on recombinant protein technology. The vaccine demonstrated strong protective effects and a high safety profile in vaccinated individuals.
Clinical trials involving tens of thousands of volunteers across Phases I, II, and III positioned Nanocovax as one of Southeast Asia’s most promising COVID-19 vaccines.
Dr. Hồ Nhân’s contributions went far beyond business success - he helped advance Vietnam’s pharmaceutical biotechnology industry and inspired a new generation of scientists and entrepreneurs dedicated to innovation for the public good. His vision of accessible healthcare through biotechnology continues to guide the industry today and into the future.
